Advancements in breast cancer treatment and diagnostics

Medical advancements in breast cancer management are increasingly focusing on personalized diagnostics and targeted therapies. Research from the OPTIMA study suggests that the Prosigna genetic test, which utilizes the PAM50 signature to analyze gene expression, may allow over half of women with common early-stage breast cancer to avoid chemotherapy. Furthermore, the FDA has approved a new pill combination of imlunestrant and abemaciclib for adult patients with specific metastatic ER-positive, HER2-negative breast cancer.

In Japan, the evolution of treatment is driving shifts in patient care and healthcare infrastructure. The use of molecular targeted drugs, antibody-drug conjugates, and immune checkpoint inhibitors is making treatment more personalized. As surgical hospital stays shorten, there is a growing trend toward outpatient chemotherapy and long-term preventative care, prompting discussions regarding the need to adjust insurance coverage to support long-term recovery. Additionally, there is an increasing emphasis on early detection and ‘appearance care’ to help patients manage the physical and psychological challenges of treatment.